Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rHMPV-Pa
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
rHMPV-Pa is an experimental live attenuated recombinant vaccine candidate for human metapneumovirus (HMPV). It is a chimeric virus in which the phosphoprotein (P) gene of HMPV has been replaced by the P gene from avian metapneumovirus (AMPV) subtype C, while all other proteins are derived from HMPV. This genetic modification confers host range attenuation, restricting replication and enhancing safety as a live intranasal vaccine. rHMPV-Pa was designed to induce both local and systemic immune responses against HMPV, aiming to protect infants and children from lower respiratory tract infections caused by this virus. In preclinical studies, it showed efficient replication in vitro and strong immunogenicity in animal models; however, phase I clinical trials revealed that it was overattenuated in seronegative children—the primary target population—resulting in insufficient immunogenicity[1][3][6]. The vaccine is not approved for use but serves as a benchmark for future live attenuated HMPV vaccine development.
- Other names
- recombinant human metapneumovirus Pachimeric HMPV vaccine with avian MPV P protein
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))αVβ1 (Integrin alpha-V beta-1)hMPV (Human metapneumovirus)
Beyond the preview
Go deeper on rHMPV-Pa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rHMPV-Pa.